CPAP therapy may improve HFpEF-like features in coronary artery disease with obstructive sleep apnea: A randomized controlled trial.

Sleep MedJun 4, 2026 (epub)
Clinical ResearchCardiologyPulmonology

Aylin Pihtili, Helena Glantz, Erik Thunström et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the effects of CPAP therapy on HFpEF-like features in 177 revascularized CAD patients with obstructive sleep apnea. At 12 months, 38.7% of patients receiving CPAP showed improvement in HFpEF-like status compared to 20.3% in the no-CPAP group (p = 0.023).

Key findings

  • HFpEF-like features were present in 71.2% of patients, with no significant difference between CPAP and no-CPAP groups.
  • Improvement in HFpEF-like status occurred in 38.7% of CPAP patients versus 20.3% in the no-CPAP group (p = 0.023).
  • CPAP therapy was independently associated with HFpEF improvement (OR 2.85; p = 0.027).
  • Higher baseline NT-proBNP levels were inversely associated with improvement (OR 0.37; p = 0.002).

Why it matters

The study highlights the potential for CPAP therapy to improve heart failure characteristics in patients with CAD and obstructive sleep apnea, suggesting a modifiable aspect of HFpEF that may enhance patient outcomes.

Source

PubMed · PMID 42250441

Published in Sleep Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.